NanoTemper Technologies and PharmAI Launch Proto, a Free AI Tool to Quickly Determine Which Protein Labeling Strategy Works Best for Molecular Interaction Measurements

NanoTemper Technologies, in partnership with PharmAI, announced the launch of Proto, a free AI-based web application that reveals the best labeling strategy to help scientists more efficiently measure molecular interactions, a process that’s necessary to discover and develop new drugs. Proto is one of the first commercial applications using the AlphaFold protein structure database that was made freely accessible by EMBL-EBI and DeepMind, an Alphabet company.

Latest Aithority Insights : MATRIXX Software and CompaxDigital Join Forces to Drive New Revenue Growth for Emerging 5G Services

“We want to help optimize research into diseases and therapeutics — that’s why we are making the tool free of charge”

Scientists in drug discovery need to detect and measure how well proteins bind to molecules, which requires labeling, usually with the aid of a dye. If the wrong labeling strategy is chosen, it leads to time-consuming and costly investigations.

Browse The Complete News About Aithority: Comau Introduces Its N-220-2.7 New Generation Robot To Unlock Higher Performance And Cost-effective…

“Proto makes use of more than 700,000 protein structures from AlphaFold or from the RCSB Protein Data Bank to suggest the appropriate dye for binding measurements,” explains Christina Wolf, Data Scientist at NanoTemper. “This makes binding measurements more efficient and reliable, and it gives scientists additional confidence in their results.”

This novel labeling prediction is another important step towards optimizing experiments in the field of biotechnology and the pharmaceutical industry with the help of artificial intelligence. “We want to help optimize research into diseases and therapeutics — that’s why we are making the tool free of charge,” says Philipp Baaske, Co-CEO of NanoTemper. “There are numerous rare diseases that are currently unprofitable for large pharmaceutical companies to study. The possibilities offered by AI-based software could enable smaller laboratories to enter the field of drug research in the future and make new therapies possible with their work, benefiting us all,” adds Joachim Haupt, CEO of PharmAI.

Read More About Aithority News : Oriient Announces New Partnership with Google Cloud to Bring Cutting-Edge Micro-Location Services to…

 [To share your insights with us, please write to sghosh@martechseries.com]